EGFR and non-small cell lung carcinoma: During treatment of NSCLC patients with first‐generation EGFR‐TKIs, serial assessment of EGFR mutations in plasma ctDNA has proved successful in allowing early detection of T790M‐driven resistance prior to radiographic progression (Oxnard et al, 2014; Mok et al, 2015).